They used 2-DE coupled MS to show that the treatment of SU11274, a cMET inhibitor along with anti-myeloma drugs (Bortezomib and Lenalidomide) downregulates the levels of angiogenic proteins such as annexin A4 (ANXA4) and prohibitin (PHB), peroxiredoxin-6 (PRDX6), and annexin A2 (ANXA2), while it upregulates the level of calpain small subunit 1 (CPNS1). This evidence concerns the gene ANXA2 and plasma cell myeloma.